Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-CMV: Extended Anti-CMV Prophylaxis in High-Risk Lung Transplant Recipients
jRCT1021250027Recruiting
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of valganciclovir and letermovir in cytomegalovirus disease (CMV) (2 arms). Primary endpoint: Incidence of CMV infection at 2 years post-transplant. Started Nov 2025; status: recruiting.
02
Drugs
valganciclovirletermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCT1021250027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1021250027.